Rochester,NY 8/10/2009 11:11:24 PM
Marshall Edwards, Inc., MSHL - Marshall Edwards and Novogen Limited concluded a license agreement for Anti-Cancer Compound
Marshall Edwards, Inc.
Marshall Edwards, Inc.and Novogen Limited have made a license agreement for Marshall Edwards to develop and commercialize the NV-128 oncology compound.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Sign up for our free alerts newsletter.
NV-128 is a cancer compound which has been shown in pre-clinical studies to promote cancer cell death in multi-drug resistant cancer cells by inducing caspase-independent DNA degradation and cancer cell death via the AKT-mTOR pathway.
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
